Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Cash & Current Investments: 2021-2024

Historic Cash & Current Investments for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Dec 2024 value amounting to $176.5 million.

  • Amylyx Pharmaceuticals' Cash & Current Investments rose 46.76% to $344.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $905.4 million, marking a year-over-year decrease of 29.75%. This contributed to the annual value of $176.5 million for FY2024, which is 52.47% down from last year.
  • Per Amylyx Pharmaceuticals' latest filing, its Cash & Current Investments stood at $176.5 million for FY2024, which was down 52.47% from $371.4 million recorded in FY2023.
  • Amylyx Pharmaceuticals' Cash & Current Investments' 5-year high stood at $371.4 million during FY2023, with a 5-year trough of $96.1 million in FY2021.
  • Over the past 3 years, Amylyx Pharmaceuticals' median Cash & Current Investments value was $346.9 million (recorded in 2022), while the average stood at $298.3 million.
  • As far as peak fluctuations go, Amylyx Pharmaceuticals' Cash & Current Investments surged by 260.96% in 2022, and later crashed by 52.47% in 2024.
  • Yearly analysis of 4 years shows Amylyx Pharmaceuticals' Cash & Current Investments stood at $96.1 million in 2021, then skyrocketed by 260.96% to $346.9 million in 2022, then increased by 7.04% to $371.4 million in 2023, then crashed by 52.47% to $176.5 million in 2024.